AUSTIN, Texas—Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), a company whose stock has delivered an impressive 154% return year-to-date according to InvestingPro, recently executed a series of stock transactions involving the company's common stock. On December 20, 2024, Moshkevich acquired a total of 4,719 shares through the vesting of Restricted Stock Units (RSUs) at no cost. These RSUs were granted based on a combination of time passage and business performance criteria.
Following these acquisitions, Moshkevich proceeded to sell a total of 2,428 shares on December 23, 2024. The shares were sold at prices ranging from $158.0626 to $159.6041 per share, resulting in total proceeds of $387,511. The sale was conducted to satisfy tax withholding obligations associated with the RSU vesting. The transaction occurred as Natera's stock maintains strong momentum, with a 45% gain over the past six months.
These transactions were carried out under a pre-established trading plan intended to comply with Rule 10b5-1(c) under the Exchange Act. After these transactions, Moshkevich holds 116,997 shares of Natera common stock. For deeper insights into Natera's valuation and 12 additional exclusive ProTips, visit InvestingPro, where you'll find comprehensive analysis in our Pro Research Report.
In other recent news, Natera Inc (NASDAQ:NTRA). has expanded its patent infringement lawsuit against NeoGenomics (NASDAQ:NEO), Inc. over the RaDaR assay. The company has also reported impressive Q3 earnings, with a 64% year-over-year increase in revenue to $439.8 million and a record high gross margin of 62%. This positive financial performance has led to a revision of its full-year revenue guidance to between $1.61 billion and $1.64 billion.
Additionally, Natera has amended its agreement with Executive Chairman, Dr. Rabinowitz, guaranteeing his continued role in the company. However, the company faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH), with plans to request the court to overturn the ruling.
Analysts from TD Cowen, Baird, and Jefferies have shown confidence in Natera's performance, maintaining favorable ratings and raising their price targets. These recent developments highlight Natera's ongoing activities and potential future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.